AVnerGene offers AAV capsid screening and evolution services through its ATHENA platform(ATHENA I and II). This platform allows for the high-throughput screening of AAV capsid libraries to identify the most efficient capsids for specific cell types or tissues. The ATHENA platform uses advanced techniques such as next-generation sequencing (NGS) to analyze the capsids and select the most promising candidates. AAVnerGene can also use directed evolution strategies to improve AAV capsid properties, such as tissue tropism and transduction efficiency, to better meet the needs of specific gene therapy applications.
AAVnerGene offers AAV capsid screening services for various animal model and cell lines, including mouse, non-human primate, and human cell lines and primary cells. This allows customers to select the best AAV capsid for their specific research or therapeutic needs, based on the target tissue or disease. The screening process can be customized based on the specific requirements of the customer’s project, and AAVnerGene’s experienced team can provide guidance and technical support throughout the process.
AAVnerGene has extensive experience in NGS library preparation and analysis. Our team is skilled in designing and constructing high-quality libraries for AAV capsid screening, as well as performing thorough analysis of the sequencing data. We use state-of-the-art sequencing technologies and bioinformatics tools to ensure accurate and reliable results. Our NGS library preparation and analysis services are available to customers who want to screen AAV capsids for their gene therapy applications.